Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.05.05.539559

Anticancer, anti-inflammatory, and immune modulatory activity of ferulic acid fructo-oligosaccharide conjugated microparticle

Johnson, E. M.·Jayabalan, R.·Patra, S.·Suh, J.-W.
View original source ↗Export metadata ↓

Abstract

Background and purposeFerulic acid exhibit anticancer activity but almost most of the free ferulic acid taken orally are absorbed in the stomach and extensively metabolised by the liver and hence hardly any free ferulic acid reach the large intestine to exert its beneficial activity. Fructo-oligosaccharide (dietary fibre) are resistant to gastro-intestinal enzymes and are poorly absorbed by the stomach but bioavailable in the large intestine where they are digested by gut microbiota. Ferulic acid fructo-oligosaccharide conjugate was synthesized which could self-assemble in to disc shaped amorphous microparticles, it was found to be resistant to gastro-intestinal enzymes and digestion by gut microbiota. The synthesized microparticles could be used for targeted delivery to the colon and accessed for its ability to ameliorate colo-rectal cancer and inflammation. Experimental approachThe anti-cancer activity of the FA FOS microparticle (FA FOS I) was tested in human colon cancer cell lines HT29, LoVo and compared with the toxicity to normal human colon fibroblast CCD18-Co, relative to that of conventional chemotherapeutic colon cancer drug oxaliplatin. The apoptosis induction by FA FOS I was assessed by TUNNEL (Terminal deoxynucleotidyl transferase mediated dUTP Nick-end Labelling) and FACS. The ability of the FA FOS microparticle to induce cell cycle arrest was determined. The gene expression profiling of both apoptosis related genes and cell cycle arrest related genes were analysed by using RT-PCR analysis of an array of apoptosis related genes and cell cycle related genes. In-vivo pre-clinical anti-colorectal cancer studies of FA FOS I microparticle were carried out in AOM-DSS mediated colitis associated colon cancer mice model (AOM DSS CAC) to determine its anti-cancer efficacy in the physiological, immunological and innate host microbiota setting. Key resultsThe in-vitro studies in colon cancer and normal colon cells exhibited selective cytotoxicity and apoptosis induction in colon cancer cells. The microparticle arrested the cell cycle in the G0-G1 phase. There was a reduction in 60.83% of tumour lesions in FA FOS I treated group compared to control group. The H&E histochemistry of the colon tissue revealed that there was 48.27% reduction in the malignant cell or tumour cells in the colon tissue on treatment with FA FOS I. The FA FOS conjugate treatment enhanced the gut barrier function and tight junction with the intestinal barrier guarded by the mucosal lining. The immunohistochemistry (IHC) and the immunofluorescence of the mouse colon tissue revealed the suppression of inflammation and related inflammatory cytokines in the colon. The inhibition of cell proliferation, up-regulation of tumour suppressor protein and apoptosis of the malignant or tumour cells were detected and quantified by IHC and TUNEL staining. The evaluation of immune status of the AOM DSS CAC mouse treated with FA FOS I microparticle was determined using haematological analysis of the blood lymphocytes which revealed a 9% increase in WBC count and the multiplex immunofluorescence of the colon tissue revealed an increase in the infiltration of T-helper cells and cytotoxic T-cells into the tumour microenvironment followed by the cells of the innate immune system. There was a considerable decrease in the expression of tumour suppressing PD-L1 by the tumour cells on four weeks treatment with FA FOS I microparticle. Conclusion and implicationsAll these data implicate better efficacy of the FA FOS I microparticle delivery to colon and amelioration of colo-rectal cancer, inflammation, and positive immune modulation of tumour microenvironment against tumour proliferation.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Johnson, E. M., Jayabalan, R., Patra, S., Suh, J.-W.. 2023-05-08. Anticancer, anti-inflammatory, and immune modulatory activity of ferulic acid fructo-oligosaccharide conjugated microparticle. https://doi.org/10.1101/2023.05.05.539559

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models

Immunotherapies, including oncolytic viruses (OV), are promising therapies that can enhance anti-tumor immune responses. However, preclinical success of immunotherapies in mouse models has not always translated to clinical benefit in cancer patients. This study compared preclinical efficacy and mechanism of action for ASP9801, a vaccinia virus expressing IL-7 and IL-12, using mouse models of colorectal cancer (CRC) in vivo and in human organotypic tumor slice models ex vivo. The murine surrogate for ASP9801 significantly reduced tumor volumes in treated and abscopal tumors in two different CRC models in vivo (MC38 and RO100). Treatment efficacy was accentuated when combined with anti-PD1 treatment, and single-cell RNA sequencing analysis revealed depletion of tumor cells and increased T cell infiltration and activation in both treated and abscopal tumors. However, human tissue analysis ex vivo (E-slices) using PDX models and patient samples showed that ASP9801 is not effective in CRC, consistent with clinical trial results. On the other hand, ASP9801 was highly effective in GBM, indicating indication-specific efficacy of ASP9801, and how E-slice assays can be used to identify treatment-sensitive indications. This study demonstrates the superiority of E-slices over mouse models for predicting clinical response and its utility in planning clinical trials.

cancer biology↗
bioRxiv2026

Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class I

Immunotherapy has transformed treatment for many cancers. In the aggressive and genetically heterogeneous diffuse large B-cell lymphoma (DLBCL), CD19 CAR T-cell therapy is highly effective, whereas immune checkpoint blockade has shown limited benefit. Loss of MHC expression is a common mechanism to escape T-cell cytotoxicity, and loss of MHC class I (MHC-I) and II are frequent in DLBCL. We applied imaging mass cytometry to diagnostic biopsies from younger, high-risk DLBCL patients to map the tumor microenvironment (TME) spatial architecture in relation to tumor cell MHC expression, mutational status, transcriptomic and proteomic profiles. Neighborhood analyses identified four TME subtypes: immune-cell depleted and three immune-infiltrated types (mixed, CD4 T cell-rich, CD8 T-cell/macrophage-rich). Depleted cases had shorter overall survival (p = 0.033) and increased expression of proteins involved in DNA replication and proliferation markers compared to infiltrated cases. Tumor cell MHC-I expression was heterogeneous. Cases with low frequency of MHC-I-pos tumor cells were enriched for the depleted TME type. MHC-I-pos tumor cells were surrounded by CD4 and CD8 T cells and M1 macrophages, whereas MHC-I-neg tumor cells were closer to other MHC-I-neg tumor cells. These findings suggest that TME-based classification incorporating tumor cell MHC-I status may improve individualized immunotherapy selection.

cancer biology↗
bioRxiv2026

Cross-species analysis links cell-cell communication rewiring to NOTCH2 during serous endometrial carcinogenesis

Cell-cell interactions shape the fate of mutant cells during cancer initiation but how these interactions evolve during progression to pathologically recognizable lesions remain poorly understood. Here, we investigated cell-cell communication during serous endometrial carcinoma (SEC; also known as uterine serous carcinoma) development using a lineage-traceable mouse model and cross-species analyses of the mouse and human neoplastic endometrium. In mice, the early, pre-dysplastic stage was marked by a global decrease in inferred cell-cell interactions, followed by extensive communication network rewiring during neoplastic progression. Pathway-specific analysis revealed a similar pattern for NOTCH signaling, with NOTCH2 emerging as the dominant NOTCH receptor in Trp53/Rb1-mutant immature epithelial cells. Functionally, NOTCH2 promoted the outgrowth of more proliferative mutant organoids. Cross-species transcriptomic analysis identified conserved immature epithelial states in mouse and human neoplastic endometrial epithelium. In human tissues, NOTCH2 was overexpressed in serous endometrial intraepithelial carcinoma, a precursor of SEC, and in overt SEC. Furthermore, elevated NOTCH2 expression was associated with poor patient survival. These findings link cell-cell communication rewiring during experimental SEC development to conserved neoplastic epithelial states and identify NOTCH2 as an early marker and a potential target of disease interception.

cancer biology↗